---
title: Treatment of CFS & Fibromyalgia With Recovery Factors
nct_id: NCT04381793
overall_status: COMPLETED
phase: NA
sponsor: Practitioners Alliance Network
study_type: INTERVENTIONAL
primary_condition: Fibromyalgia
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04381793.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04381793"
ct_last_update_post_date: 2020-10-19
last_seen_at: "2026-05-12T06:38:47.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment of CFS & Fibromyalgia With Recovery Factors

**NCT ID:** [NCT04381793](https://clinicaltrials.gov/study/NCT04381793)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 43
- **Lead Sponsor:** Practitioners Alliance Network
- **Conditions:** Fibromyalgia, Chronic Fatigue Syndrome
- **Start Date:** 2019-05-20
- **Completion Date:** 2020-07-04
- **CT.gov Last Update:** 2020-10-19

## Brief Summary

The study will explore if Recovery Factors improve symptoms in fibromyalgia and chronic fatigue syndrome

## Detailed Description

Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Meet ACR 2010 amended Fibromyalgia criteria or CDC CFS Criteria Overall well being score of 5 of less (on 0-10 VAS)

Exclusion Criteria:

Pregnant Clotting disorders

\-
```

## Arms

- **Assessing clinical efficacy** (EXPERIMENTAL) — Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects

## Interventions

- **Recovery Factors** (DIETARY_SUPPLEMENT) — Porcine serum amino acid/peptide

## Primary Outcomes

- **VAS** _(time frame: 6 weeks)_ — Composite VAS (1-10) for Fatigue, Pain, Cognition, Sleep and overall well-being

## Secondary Outcomes

- **antibody titres** _(time frame: 10 weeks)_
- **FIQ-R** _(time frame: 6 weeks)_

## Locations (1)

- Jacob Teitelbaum MD, Kailua, Hawaii, United States

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.jacob teitelbaum md|kailua|hawaii|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04381793.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04381793*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*